Received Jul 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Shingrix - Redness close to injection site; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site erythema in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site erythema (Verbatim: Shingrix - Redness close to injection site). The outcome of the injection site erythema was unknown. It was unknown if the reporter considered the injection site erythema to be related to Shingrix. It was unknown if the company considered the injection site erythema to be related to Shingrix. Additional Information: GSK Receipt Date: 27-JUN-2025 A pharmacist mentioned that a patient reported redness close to the injection site. The pharmacist said that redness was few inches down to the injection site. This patient received the first dose of Shingrix between 21-28 days ago (did not provide specific date of administration). The pharmacist mentioned that patient was in her early 70s (not specific age provided). No further details provided. The reporter consented to follow up.